Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators expect to better characterise B cell subpopulation and functional properties early after graft, to analyse effect of induction therapy (thymoglobulin versus basiliximab) on B cells, and to compare this B cell profiles with those obtained in our previous study in patients with chronic Antibody Mediated Rejection (cAMR)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Thymoglobulin Induction | Patient receiving thymoglobulin as an induction therapy for renal transplant |
| |
| Basiliximab Induction | Patient receiving basiliximab as an induction therapy for renal transplant |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Thymoglobulin Induction | Drug | The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study. |
| Measure | Description | Time Frame |
|---|---|---|
| The distribution of mature blood B cells subpopulations will be compared between the 2 groups | one year after renal transplant | |
| Proliferation of freshly isolated cells T in presence of autologous B cells will be compared between the 2 groups. | one year after renal transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Serum B-cell activating factor (BAFF) concentration comparison between the two groups | one year after renal transplant |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
kidney graft recipients from two French renal transplantation centers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yannick Le meur | University Hospital, Brest | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Brest | Brest | 29200 | France | |||
| Tours University Hospital |
Not provided
Not provided
Not provided
Not provided
Whole blood
|
| Basiliximab Induction | Drug | The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study. |
|
| Tours |
| 37000 |
| France |